Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,034.54 -37.09 (-0.73%) Dow
38,002.05 -458.87 (-1.19%) Nasdaq
15,551.10 -161.65 (-1.03%) Bitcoin USD
64,438.83 -264.70 (-0.41%) CMC Crypto 200
1,386.94 +4.37 (+0.32%)
REGN Jan 2025 770.000 call
| Previous close | 134.14 |
| Open | 134.14 |
| Bid | 142.80 |
| Ask | 147.80 |
| Strike | 770.00 |
| Expiry date | 2025-01-17 |
| Day's range | 134.14 - 134.14 |
| Contract range | N/A |
| Volume | |
| Open interest | 29 |
ZacksRegeneron (REGN) Reports Next Week: What You Should Expect
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Reuters
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
ZacksThe Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power are part of the Zacks top Analyst Blog.
